ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2012
Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma.
Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas.Scientific reports · 2018Pooled it
- Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.British journal of cancer · 2015Pooled it
- Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.BMC cancer · 2016Trial
- Cyclooxygenase-2 Overexpression and its Association with Histopathological Features of Human Malignant Melanoma.Iranian journal of pathology · 2025Article
- Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy.Acta pharmaceutica Sinica. B · 2022Review
- Effect of perioperative flurbiprofen axetil on long-term survival of patients with esophageal carcinoma who underwent thoracoscopic esophagectomy: A retrospective study.Journal of surgical oncology · 2021Article
- Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer.OncoTargets and therapy · 2019Article
- The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis.OncoTargets and therapy · 2017Review
- The tumor microenvironment in esophageal cancer.Oncogene · 2016Review
- Current and emerging therapies in unresectable and recurrent gastric cancer.World journal of gastroenterology · 2016Review
- New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.Journal of mammary gland biology and neoplasia · 2015Review
- Analysis of the correlation between P53 and Cox-2 expression and prognosis in esophageal cancer.Oncology letters · 2015Article
- Cyclooxygenase-2--An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma--An Immunohistochemical Study.Pathology oncology research : POR · 2015Article
- Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade.British journal of cancer · 2014Article
- Article
- Cross-species array comparative genomic hybridization identifies novel oncogenic events in zebrafish and human embryonal rhabdomyosarcoma.PLoS genetics · 2013Article
- Predictive value of vascular endothelial growth factor overexpression in early relapse of colorectal cancer patients after curative resection.International journal of colorectal disease · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyclooxygenase isoenzyme-2 (COX-2) and vascular endothelial growth factor (VEGF) contribute to angiogenesis and are overexpressed in various malignancies. The aim of the study was to evaluate expression, prognostic value and correlation between COX-2 and VEGF expression in esophageal adenocarcinoma (EAC).
methodsSurgical specimens of 154 patients with EAC were used to construct a tissue micro array (TMA). TMA sections were immunohistochemically stained for COX-2 and VEGF and scored on intensity of staining.
resultsEstimated 5-year cancer specific survival was 37%. High COX-2 and VEGF expression was observed in 39 (26.5%) and in 77 (53.8%) tumors, respectively. Both markers were associated with poor cancer specific survival (p = .022 and p = .004, respectively, log rank). No significant correlation was found between VEGF and COX-2 expression (r = 063; p = .455). In multivariate analysis, high COX-2 expression (HR 1.65; 95% CI 1.04-2.61; p = .034) was associated with overall survival. In patients with T3 tumors, COX-2 expression was an independent prognostic factor for cancer specific survival (HR 1.81 95% CI 1.10-2.95; p = .019).
conclusionsThis is the first study that evaluated the prognostic value and correlation of COX-2 and VEGF expression in a large and homogenous population of patients with EAC. No correlation between COX-2 and VEGF expression was found. Both markers were expressed in EAC and were associated with poor prognosis. The findings support the use of COX-2 and VEGF inhibitors in future clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.